NOX.AX
Price:
$0.083
Market Cap:
$24.26M
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of vario...[Read more]
Industry
Biotechnology
IPO Date
2016-08-09
Stock Exchange
ASX
Ticker
NOX.AX
According to Noxopharm Limited’s latest financial reports and current stock price. The company's current PE Ratio is -8.30. This represents a change of 276.60% compared to the average of -2.20 of the last 4 quarters.
The mean historical PE Ratio of Noxopharm Limited over the last ten years is -15.59. The current -8.30 PE Ratio has changed 5.22% with respect to the historical average. Over the past ten years (40 quarters), NOX.AX's PE Ratio was at its highest in in the June 2020 quarter at 1.32. The PE Ratio was at its lowest in in the June 2021 quarter at -17.71.
Average
-15.59
Median
-5.66
Minimum
-83.90
Maximum
-0.83
Discovering the peaks and valleys of Noxopharm Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.38%
Maximum Annual PE Ratio = -0.83
Minimum Annual Increase = -83.29%
Minimum Annual PE Ratio = -83.90
Year | PE Ratio | Change |
---|---|---|
2024 | -5.39 | 545.91% |
2023 | -0.83 | -72.57% |
2022 | -3.04 | -83.29% |
2021 | -18.21 | -78.30% |
2020 | -83.90 | 1.38% |
2019 | -5.66 | 42.59% |
2018 | -3.97 | -62.16% |
2017 | -10.49 | 19.11% |
The current PE Ratio of Noxopharm Limited (NOX.AX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.09
5-year avg
-22.28
10-year avg
-15.59
Noxopharm Limited’s PE Ratio is greater than Orthocell Limited (-38.32), less than Antisense Therapeutics Limited (0), greater than Race Oncology Limited (-15.31), less than Prescient Therapeutics Limited (-4.69), less than Recce Pharmaceuticals Ltd (-5.49),
Company | PE Ratio | Market cap |
---|---|---|
-38.32 | $340.38M | |
0 | $52.29M | |
-15.31 | $222.35M | |
-4.69 | $38.66M | |
-5.49 | $110.14M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Noxopharm Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Noxopharm Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Noxopharm Limited's PE Ratio?
How is the PE Ratio calculated for Noxopharm Limited (NOX.AX)?
What is the highest PE Ratio for Noxopharm Limited (NOX.AX)?
What is the 3-year average PE Ratio for Noxopharm Limited (NOX.AX)?
What is the 5-year average PE Ratio for Noxopharm Limited (NOX.AX)?
How does the current PE Ratio for Noxopharm Limited (NOX.AX) compare to its historical average?